Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141063 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD
A Phase 3 study of ADHD, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT00141063: Completed Phase 3 study of ADHD, sponsored by Novartis.
NCT00141063 is a Phase 3 study of ADHD that has completed, run by Novartis. The registered enrollment target is 90 participants, below the 189-participant average among 75 other ADHD trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00141063, a Phase 3 study of ADHD, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the safety and efficacy of two doses of dexmethylphenidate to two doses of an approved, long-acting, marketed medication for ADHD (MPH) and placebo in children ages 6-12 diagnosed with ADHD.
Conditions Studied
Interventions
- DRUG Focalin XR
Study Locations (1)
Nevada
- Center for Psychiatry & Behavioral Medicine - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2005-06 |
| Est. Completion | 2005-08 |
| Phase | Phase 3 |
What the finished NCT00141063 record still lists
NCT00141063 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 189-participant average among 75 other ADHD trials with a reported enrollment target (52% lower).
The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 1 intervention - of which Focalin XR is the first listed.
NCT00141063 reports a single indexed study location in Nevada.
Frequently Asked Questions
What is clinical trial NCT00141063 about?
NCT00141063 is a clinical study titled "Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD". The purpose of this study is to compare the safety and efficacy of two doses of dexmethylphenidate to two doses of an approved, long-acting, marketed medication for ADHD (MPH) and placebo in children ages 6-12 diagnosed with ADHD.
What is the current status of trial NCT00141063?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2005-06. Estimated completion is 2005-08.
What conditions does trial NCT00141063 study?
This clinical trial studies the following conditions: ADHD.
What interventions are being tested in trial NCT00141063?
The interventions under investigation include: Focalin XR (DRUG).
Who is sponsoring clinical trial NCT00141063?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00141063 being conducted?
This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ADHD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00141063's enrollment target sits among peer trials
90 36th of 75 higher than 39 of 75 other ADHD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other ADHD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
RECRUITING · Phase 3
-
Treating Parents with ADHD and Their Young Children Via Telehealth: a Hybrid Type I Effectiveness-Implementation Trial
ACTIVE NOT RECRUITING · Phase 3
-
Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
-
Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD
COMPLETED · Phase 3
-
PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
-
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia